Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of 14C-aticaprant in healthy men
NCT05197062Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aticaprant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma Concentrations of Aticaprant and its Metabolite M3, Duodenal Concentrations of Aticaprant and its Metabolite M3 and 6 more. Started Jan 2022; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05197062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197062.